Zealand Pharma Shares Slip After Jefferies Downgrade and Shrinking Outlook for Survodutide
Zealand Pharma shares moved lower after Jefferies downgraded the stock from Buy to Hold and cut its price target to DKK 320 from DKK 505, citing a lack of near-term value-crystallising events in the second half of 2026 and lowering the probability of success for survodutide to 40% from 60%. The downgrade compounded earlier analyst concerns over sur…